Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Akoya Biosciences Inc (NQ: AKYA )

2.920 +0.070 (+2.46%)
Streaming Delayed Price Updated: 3:19 PM EDT, Oct 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Akoya Biosciences Inc

< Previous 1 2 Next >
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Reports Second Quarter 2024 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Reports First Quarter 2024 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
Leveraging Akoya’s market-leading PhenoImager HT platform and clinical development expertise with NeraCare’s Immunoprint test and best-in-class clinical data, the partnership will focus on increasing... 
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows
KR-HT5 is based on Akoya’s PhenoImager® HT Platform 
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases
PhenoCycler®-Fusion system selected as the Centre’s platform technology for advanced spatial biology studies 
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board
Leading immunotherapy and immunobiology experts will offer strategic direction and expertise in translational, clinical, and diagnostic applications of Akoya’s spatial biology solutions 
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow
The Thermo Fisher Scientific ViewRNA technology combined with Akoya’s market leading spatial biology solutions will enable rapid, whole-slide imaging of RNA and protein biomarkers 
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Participate at Three Upcoming Investor Conferences
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Announces Peer-Reviewed Publication Using Ultrahigh-Plex Spatial Phenotyping of Head and Neck Cancer to Identify Distinct Immune and Metabolic Signatures
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Report Third Quarter 2023 Financial Results on November 8th, 2023
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Reports Record Revenue in the Second Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Participate at Three Upcoming Investor Conferences
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Report Second Quarter 2023 Financial Results on August 7th, 2023
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Participate at Two Upcoming Investor Conferences
From Akoya Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.